Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up

This Phase II trial with a long-term follow-up revealed that some patients with hormone refractory prostate cancer could obtain durable disease response and long survival with an oral etoposide and estramustine combination regimen.